Updating results…
What is ALS Phase 2 Study KNS-760704 CL211?
NCT00931944 is an open label, safety and tolerability, study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID include: KNS-760704-CL211.
Reported Purpose & Perceived Effectiveness
| Perceived Effectiveness | |||||||
|---|---|---|---|---|---|---|---|
| Purpose | # of patients | # of patients with evaluations | Major | Moderate | Slight | None | Can’t tell |
| Participate in clinical trial | 1 | 1 |
|
||||
Mouse over the table for more information
Reported Side Effects
Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 2 Study KNS-760704 CL211
| Ringing in ears (tinnitus) | 1 | |
|---|---|---|
| Loss of appetite | 1 |
Reported Stop Reasons
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 1 |  |
|
| Course of treatment ended | 1 | |
See all 1 patient who’ve stopped using ALS Phase 2 Study KNS-760704 CL211
Reported Duration See details about how long patients take this treatment ▼
Stopped Using ALS Phase 2 Study KNS-760704 CL211
A bar graph
| 0-1 month | 1-3 months | 3-6 months | 6 months-1year | 1-2 years | 2 years or more |
|---|---|---|---|---|---|
|
0
|
0
|
0
|
0
|
0
|
Reported Adherence, Burden & Cost See details from patient evaluations ▼
Adherence
Taking treatment as prescribed
Adherence of ALS Phase 2 Study KNS-760704 CL211
Always |
1 | 100% |
|
|---|---|---|---|
Usually |
0 | 0% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of ALS Phase 2 Study KNS-760704 CL211
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
1 | 100% |
|
A little |
0 | 0% |
|
Not at all |
0 | 0% |
|
Cost
Paid out of pocket
Cost of ALS Phase 2 Study KNS-760704 CL211
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
0 | 0% |
|
< $25 |
1 | 100% |
|